Corona “dead vaccine” Novavax: Ministry of Health names new delivery date
Created: 01/11/2022, 09:20 AM
From: Bettina Menzel
Novavax's corona vaccine.
© Tomislav Miletic / PIXSELL / Imago Images
The protein-based corona vaccine Novavax is expected to be available in Germany at the beginning of February.
However, there are still no precise delivery schedules.
Berlin - On December 20, the European Medicines Agency (EMA) recommended the approval of the first protein-based vaccine against corona from the US manufacturer Novavax.
The Ministry of Health has now announced that the Nuvaxovid vaccine will be available in Germany from the beginning of February.
The
Berliner Zeitung
reports .
Earlier, the talk was from the end of January.
Ministry of Health: "Delivery plans are not yet available"
Health Minister Karl Lauterbach (SPD) confirmed the order for four million doses of the Novavax vaccine in December and announced a delivery date "at the beginning of the year", probably at the end of January. A spokesman for the Ministry of Health told the
Berliner Zeitung
on Thursday that the vaccine is expected to be available in Germany in early February. The Ministry of Health currently has no delivery plans for the new vaccine, the spokesman for the Ministry of Health told the
Berliner Zeitung
. More specific information is not yet possible. Doctors' offices can order the vaccine as needed.
The European Commission signed a contract with the US pharmaceutical manufacturer Novavax back in August last year.
The agreement did not provide for a specific date, only the first quarter of 2022 was mentioned.
Accordingly, the US manufacturer plans to start delivering 100 million doses of its COVID-19 vaccine to the EU in the first three months of this year.
Member States have the option to secure an additional 100 million doses over the course of 2022 and 2023.
Coronavirus: Nuvaxovid effectiveness around 90 percent
In contrast to the previously approved mRNA vaccines Moderna and Pfizer / Biontech and the vector-based vaccines Astrazeneca and Johnson & Johnson, the Nuvaxovid vaccine from Novavax is protein-based. The vaccine injects virus-like particles into the body that mimic the coronavirus spike protein. This stimulates the immune system to produce targeted antibodies against Sars-Cov-2. The Nuvaxovid vaccine has been tested on over 40,000 subjects and its effectiveness is 90 percent. According to current knowledge, the second dose of the vaccine is recommended after around three weeks.
The Novavax vaccine is often referred to as a "dead vaccine".
Neither the protein-based technology nor the mRNA or vector technology contain pathogens or pathogen components, so that all corona vaccines currently approved in Europe can be equated with dead vaccines, according to the Ministry of Health.
